Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?

被引：10
|
作者：
Aprotosoaie, Ana Clara [1 ]
Costache, Alexandru-Dan [2 ,3 ]
Costache, Irina-Iuliana [3 ,4 ]
机构：
[1] Grigore T Popa Univ Med & Pharm Iasi, Fac Pharm, Iasi 700115, Romania
[2] Clin Rehabil Hosp, Dept Cardiovasc Rehabil, Iasi 700661, Romania
[3] Univ Med & Pharm Grigore T Popa, Fac Med, Dept Internal Med 1, Iasi 700115, Romania
[4] St Spiridon Emergency Cty Hosp, Dept Cardiol, Iasi 700111, Romania
来源：
PHARMACEUTICS | 2022年 / 14卷 / 04期
关键词：
atherosclerosis; pharmacotherapy; emergent therapeutics; natural anti-atherosclerotic products; RENIN-ANGIOTENSIN SYSTEM; PHOTODYNAMIC THERAPY; RISK-FACTORS; CARDIOVASCULAR-DISEASES; FAMILIAL HYPERCHOLESTEROLEMIA; ENDOTHELIAL FUNCTION; INTIMAL HYPERPLASIA; MOTEXAFIN LUTETIUM; DNA METHYLATION; CONTRAST AGENTS;
D O I：
10.3390/pharmaceutics14040722
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Despite progress in understanding the pathogenesis of atherosclerosis, the development of effective therapeutic strategies is a challenging task that requires more research to attain its full potential. This review discusses current pharmacotherapy in atherosclerosis and explores the potential of some important emerging therapies (antibody-based therapeutics, cytokine-targeting therapy, antisense oligonucleotides, photodynamic therapy and theranostics) in terms of clinical translation. A chemopreventive approach based on modern research of plant-derived products is also presented. Future perspectives on preventive and therapeutic management of atherosclerosis and the design of tailored treatments are outlined.
引用
收藏
页数：23
相关论文
共 50 条
  • [1] What do we know and where do we go?
    Vandiver, BJ
    COUNSELING PSYCHOLOGIST, 2002, 30 (01): : 96 - 104
  • [2] Ethical Judgments: What Do We Know, Where Do We Go?
    Peter E. Mudrack
    E. Sharon Mason
    Journal of Business Ethics, 2013, 115 : 575 - 597
  • [3] Implementing Exercise: What Do We Know? Where Do We Go?
    Painter, Patricia
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2009, 16 (06) : 536 - 544
  • [4] Surrogate alcohol: What do we know and where do we go?
    Lachenmeier, Dirk W.
    Rehm, Juergen
    Gmel, Gerhard
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2007, 31 (10) : 1613 - 1624
  • [5] SUICIDE IN SCHIZOPHRENIA - WHAT DO WE KNOW - WHERE DO WE GO
    WAGMAN, AMI
    SCHIZOPHRENIA RESEARCH, 1991, 4 (03) : 378 - 379
  • [6] Ethical Judgments: What Do We Know, Where Do We Go?
    Mudrack, Peter E.
    Mason, E. Sharon
    JOURNAL OF BUSINESS ETHICS, 2013, 115 (03) : 575 - 597
  • [7] Cancer and stroke: What do we know and where do we go?
    Lun, Ronda
    Siegal, Deborah
    Ramsay, Tim
    Dowlatshahi, Dar
    THROMBOSIS RESEARCH, 2022, 219 : 133 - 140
  • [8] Cannabinoids for epilepsy: What do we know and where do we go?
    Brodie, Martin J.
    Ben-Menachem, Elinor
    EPILEPSIA, 2018, 59 (02) : 291 - 296
  • [9] Round table: Ecoimmunology: what do we know, where do we go?
    Titon, S. C. M.
    Assis, V. R.
    INTEGRATIVE AND COMPARATIVE BIOLOGY, 2023, 62 : S308 - S308
  • [10] Aging and Spatial Navigation: What Do We Know and Where Do We Go?
    Scott D. Moffat
    Neuropsychology Review, 2009, 19 : 478 - 489
12345